Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All xiannuoxin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchXiannuoxinXiannuoxin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Recovery time 17% Improvement Relative Risk Xiannuoxin  Cao et al.  EARLY TREATMENT  DB RCT Is early treatment with xiannuoxin beneficial for COVID-19? Double-blind RCT 1,007 patients in China (August - December 2022) Faster recovery with xiannuoxin (p<0.000001) c19early.org Cao et al., New England J. Medicine, Jan 2023 Favors xiannuoxin Favors control

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19

Cao et al., New England Journal of Medicine, doi:10.1056/NEJMoa2301425 (press release 1/29/2023), NCT05506176
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 1,208 outpatients with mild-moderate COVID-19 in China, showing faster symptom resolution (by 35.8 hours) and faster viral clearance with xuannuoxin (simnotrelvir plus ritonavir) twice daily for 5 days.
recovery time, 16.6% lower, relative time 0.83, p < 0.001, treatment mean 180.1 (±10.1) n=504, control mean 216.0 (±6.3) n=503.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cao et al., 29 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, China, peer-reviewed, median age 35.0, 31 authors, study period 19 August, 2022 - 16 December, 2022, trial NCT05506176 (history). Contact: caobin_ben@163.com, renhong.tang@simceregroup.com, yh-birm@263.net.
This PaperXiannuoxinAll
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
M.D Bin Cao, M.D Yeming Wang, M.D Hongzhou Lu, M.D Chaolin Huang, M.D Yumei Yang, Ph.D Lianhan Shang, M.D Zhu Chen, M.D Rongmeng Jiang, M.D Yihe Liu, M.D Ling Lin, M.D Ping Peng, M.D Fuxiang Wang, M.D Fengyun Gong, M.D Honglin Hu, M.S Cong Cheng, M.D Xiangyang Yao, M.D Xianwei Ye, M.D Hourong Zhou, M.D Yinzhong Shen, M.D Chenfan Liu, M.D Chunying Wang, M.D Zhennan Yi, M.D Bijie Hu, M.D Jiuyang Xu, M.D Xiaoying Gu, Ph.D Jingshan Shen, Ph.D Yechun Xu, Ph.D Leike Zhang, Ph.D Jia Fan, M.D Renhong Tang, Ph.D Chen Wang
New England Journal of Medicine, doi:10.1056/nejmoa2301425
BACKGROUND Simnotrelvir is an oral 3-chymotrypsin-like protease inhibitor that has been found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy in a phase 1B trial. CONCLUSIONS Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns.
Appendix
References
Akhmerov, Marbán, COVID-19 and the heart, Circ Res
Arbel, Sagy, Hoshen, Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge, N Engl J Med
Butler, Hobbs, Gbinigie, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an openlabel, platform-adaptive randomised controlled trial, Lancet
Cao, Gao, Bao, VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19, N Engl J Med
Cao, Jian, Wang, Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution, Nature
Garcia-Beltran, Lam, Denis, Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, Cell
Huang, Li, Gu, Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study, Lancet Respir Med
Islam, Riaz, Efa, Farjana, Mahmood, Health-related quality of life of the adult COVID-19 patients following one-month illness experience since diagnosis: findings of a cross-sectional study in Bangladesh, PLoS One
Jiang, Su, Shang, Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir, Nat Commun
Mukae, Yotsuyanagi, Ohmagari, A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part, Antimicrob Agents Chemother
O'brien, Fleming, A multiple testing procedure for clinical trials, Biometrics
Pfizer, Analyst and investor call to discuss the first COVID-19 comprehensive approach: Pfizer-BioNTech vaccine and Pfizer's novel oral antiviral treatment candidate
Wang, Tang, Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial, Lancet Reg Health West Pac
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet
Yang, Yang, Yao, A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects, Eur J Pharm Sci
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit